Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

Joon Seong Park, Sung Eun Lee, Seong Hyun Jeong, Eun Jung Jang, Mi Yeon Choi, Hyeoung Joon Kim, Yeo Kyeoung Kim, Sung Hyun Kim, Dae Young Zang, Sukjoong Oh, Dong Hoe Koo, Hawk Kim, Young Rok Do, Jae Yong Kwak, Jeong A. Kim, Dae Young Kim, Yeung Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny ParkJi Hyun Kwon, Dong Wook Kim

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


The aim of this study was to investigate the changes in health-related profiles including quality-of-life (HRQoL) in the chronic myeloid leukemia (CML) patients who discontinued imatinib (IM). An HRQoL survey composed of 43 parameters about IM-related adverse events (AEs), physical health-related and mental health-related was provided at baseline and 6 months post-discontinuation. A total of 55 patients with a sustained UMRD over 6 months were analyzed. Although the majority of IM-related AEs were significantly improved, unexpectedly pruritus and musculoskeletal pain worsen or newly develop in 29.1% and 21.8% of patients, respectively. The improvements in physical and mental health condition were variable in individual patients. In addition, rapid restorations of the hematological and biochemical parameters were observed. The results showed the changes of HRQoL and laboratory tests in treatment-off patients and the necessity of continuing physical and mental support for some patients in tyrosine kinase inhibitor (TKI)-off studies.

Original languageEnglish
Pages (from-to)341-347
Number of pages7
JournalLeukemia and Lymphoma
Issue number2
StatePublished - 1 Feb 2016

Bibliographical note

Publisher Copyright:
© 2015 Informa UK, Ltd.


  • Chronic myeloid leukemia
  • imatinib cessation
  • quality-of-life


Dive into the research topics of 'Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients'. Together they form a unique fingerprint.

Cite this